Yohannes Gemechu
Overview
Explore the profile of Yohannes Gemechu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adeosun J, Shaikh M, Brauns T, Agarwala Y, Poznansky M, Gemechu Y
Trends Cancer
. 2024 Dec;
11(3):192-195.
PMID: 39672756
Shortcomings in cancer vaccine development are attributable to weak and transient anti-tumor cellular responses in the tumor microenvironment. This restriction of efficacy may be due to an intratumoral immunosuppressive milieu,...
2.
Cheval B, Gemechu Y, Shahrouzi P, Zou L
Trends Mol Med
. 2024 Dec;
30(8):699-701.
PMID: 39648584
No abstract available.
3.
Agarwala Y, Brauns T, Sluder A, Poznansky M, Gemechu Y
Trends Immunol
. 2024 Jun;
45(7):486-494.
PMID: 38876831
Immunotherapies have revolutionized the treatment of certain cancers, but challenges remain in overcoming immunotherapy resistance. Research shows that metabolic modulation of the tumor microenvironment can enhance antitumor immunity. Here, we...
4.
Colley A, Brauns T, Sluder A, Poznansky M, Gemechu Y
Trends Mol Med
. 2024 May;
30(8):765-780.
PMID: 38821771
While immunomodulatory imide drugs (IMiDs) have been authorised for treatment of haematological cancers for over two decades, the appreciation of their ability to stimulate antitumour T cell and natural killer...
5.
Nyati K, Hashimoto S, Singh S, Tekguc M, Metwally H, Liu Y, et al.
Cancer Lett
. 2021 Aug;
520:295-306.
PMID: 34389433
Interleukin (IL-6) is a pleotropic cytokine with both tumor-promoting and -inhibitory effects on breast cancer growth. However, the mechanisms governing the outcome of IL-6 on cancer progression remain to be...
6.
Metwally H, Tanaka T, Li S, Parajuli G, Kang S, Hanieh H, et al.
Sci Signal
. 2020 Mar;
13(624).
PMID: 32209697
The lipopolysaccharide (LPS)-induced endocytosis of Toll-like receptor 4 (TLR4) is an essential step in the production of interferon-β (IFN-β), which activates the transcription of antiviral response genes by STAT1 phosphorylated...
7.
Chalise J, Hashimoto S, Parajuli G, Kang S, Singh S, Gemechu Y, et al.
Proc Natl Acad Sci U S A
. 2019 Jul;
116(30):15128-15133.
PMID: 31289228
Immune cells infiltrate adipose tissues and provide a framework to regulate energy homeostasis. However, the precise underlying mechanisms and signaling by which the immune system regulates energy homeostasis in metabolic...
8.
Gemechu Y, Millrine D, Hashimoto S, Prakash J, Sanchenkova K, Metwally H, et al.
Proc Natl Acad Sci U S A
. 2018 Oct;
115(46):11802-11807.
PMID: 30373817
Immunomodulatory drugs (IMiDs), including thalidomide derivatives such as lenalidomide and pomalidomide, offer therapeutic benefit in several hematopoietic malignancies and autoimmune/inflammatory diseases. However, it is difficult to study the IMiD mechanism...
9.
Millrine D, Tei M, Gemechu Y, Kishimoto T
Proc Natl Acad Sci U S A
. 2016 Sep;
113(38):10625-30.
PMID: 27601648
Immunomodulatory drugs (IMiDs) are a family of compounds derived from thalidomide. Binding of the IMiD molecule to the Lon protease Cereblon initiates the degradation of substrates via the ubiquitin proteasome...
10.
Millrine D, Miyata H, Tei M, Dubey P, Nyati K, Nakahama T, et al.
Int Immunol
. 2016 Feb;
28(6):307-15.
PMID: 26865412
Thalidomide and its derivatives, collectively referred to as immunomodulatory drugs (IMiDs), are effective inhibitors of inflammation and are known to inhibit TLR-induced TNFα production. The identification of Cereblon as the...